#Peru #Lima #MGI Tech #Genetics Research #USMP

MGI Tech and Universidad de San Martín de Porres: A New Era in Genetics Research

In a significant milestone for genetic research, MGI Tech Co., Ltd. has formed a partnership with the Universidad de San Martín de Porres (USMP) in Lima, Peru. This collaboration aims to enhance human genetics research through the implementation of next-generation genomic sequencing (NGS) technology.

MGI Tech, renowned for its innovative tools in life science, is set to introduce advanced genomic sequencing equipment at USMP's Genetic and Molecular Biology Research Center. This state-of-the-art technology will significantly improve the accuracy and efficiency of scientific studies in Peru, enabling researchers to pinpoint genetic variations that contribute to various health conditions.

Advancements in Research Capabilities

Carlos Carpio, Commercial Director for MGI Latin America, emphasized the importance of this partnership for the Peruvian scientific community. With large-scale studies of the human genome now possible, researchers can analyze genetic data with unprecedented speed and precision. The NGS technology not only streamlines the research process—from sample preparation to bioinformatics analysis—but also reduces associated costs.

The MGI laboratory at USMP will be equipped with several cutting-edge tools, including the DNBSEQ-G400RS sequencer, the MGISP-100 automated library preparation system, and the MEGABOLT bioinformatics accelerator. These enhancements are crucial for conducting sophisticated genetic studies.

Addressing the Gap in Representation

Dr. Ricardo Fujita, Director of the Research Institute at USMP, highlighted a pressing issue within the global genetic research community: the underrepresentation of Peruvian and Andean populations. He noted that 80% of the world's populations, including those in Peru, have historically been overlooked in both medical and genomic studies.

This lack of representation hampers the identification of genetic predispositions to diseases, making it challenging to develop effective, personalized medical treatments. Notably, a recent study from USMP indicates that the average indigenous genetic heritage of the Peruvian population is around 70%.

In light of these findings, the partnership with MGI aims to close the research gap by focusing on essential areas such as rare diseases, cancer, pharmacogenomics, and the genetics of native communities.

Five Research Projects in Focus

With the new technology in place, Dr. Fujita and a team of seven researchers at USMP will embark on five ambitious research projects:
1. Rare Diseases: Investigation into a range of conditions including neurological and developmental disorders.
2. Cancer Research: Analysis of sporadic cancer cases to identify genetic predispositions and markers in the next two years.
3. Immunogenomics and Pharmacogenomics: Exploration of genetic variants in the Peruvian populace that affect infection susceptibility and drug resistance.
4. Genetics of Native Populations: Collection and analysis of 1,000 genomes from indigenous South American populations, contributing to a new Peruvian BioBank over the next four years.
5. Metagenomics: Examination of 1,000 metagenomic samples to study microbial communities and their relation to infectious diseases and the human microbiome in the Andean and Amazon regions.

Impact on Education and Training

The incorporation of MGI Tech's genomic tools at USMP not only aims to advance research but also enhance education and training opportunities in genetics and molecular biology. This endeavor is expected to cultivate the next generation of professionals equipped with skills essential for medical research and personalized healthcare, establishing USMP as a leader in genomic studies across the region.

Dr. Fujita envisions that this collaboration will spur significant advancements in genetic research and expand the understanding of health issues pertinent to Peru and its neighboring countries. By identifying specific genetic risk factors, researchers hope to pave the way for personalized treatment tailored to the local population's unique health needs.

As the world of genetics continues to evolve rapidly, this partnership represents a crucial step toward inclusivity and precision in medical research—a vital move that could lead to groundbreaking discoveries for many who have long been excluded from the global research agenda.